The medtech giant describes the Percept RC as the first DBS sensing-enable rechargeable device. In a presentation at the J.P. Morgan Healthcare Conference earlier today, CEO Geoff Martha called it a “game-changing” device that exemplifies “how Medtronic engineers are really leading the industry in innovation, developing smaller devices and inventing sensing technology to improve therapeutic benefit.”

Medtronic officials see Percept RC — and the company’s closed-loop rechargeable Inceptiv spinal cord stimulator — expanding share in what they describe as a combined $3.3 billion DBS and SCS sector.

The Medtronic Percept family already included the Percept PC neurostimulator, BrainSense technology, and SenSight directional leads. Sensing-enabled DBS through Percept enables physicians to personalize treatment for patients with movement disorders such as Parkinson’s disease, essential tremor, and dystonia — as well as epilepsy.